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71. INTRODUCTION 
For most patients with end stage kidney failure, kidney transplantation has the greatest 
potential for restoring a healthy and productive life. Furthermore, kidney transplantation 
offers a survival benefit compared to dialysis treatment in recipients of all ages (1). 
However, kidney transplant recipients still have a reduced life expectancy compared to 
the background population (2). The main problem today is the organ shortage. It is 
therefore important to identify risk factors for graft loss in order to increase the graft 
survival and decrease the need for re-transplants. The incidence of acute rejection and 
early graft failure has declined dramatically as a result of new immunosuppressive 
medications. When considering reasons for graft failures, patient death and 
cardiovascular disease in the late period after transplantation, a different set of risk 
factors apply. It is important to identify the panorama of different risk factors that operate 
at different time periods after transplantation in order to increase both graft and patient 
survival. 
1.1 Epidemiology of ESRD. 
During the last decades the availability of care for patients with ESRD has grown rapidly 
throughout the medical developed world. The number of patients receiving treatment for 
ESRD has increased steadily. Modalities for the management of ESRD population vary 
among countries. Even in the Nordic countries there are striking differences. In Norway 
71.6 % of the ESRD patients had a kidney transplant in 2005, while the corresponding 
number in Sweden was 53% (3, 4). 
The average age of the ESRD population increase each year world wide. Age has not 
been a factor for patient selection in Norway during the last two decades.  In Europe the 
majority of the dialysis patients are men while there is only a small difference among the 
sexes in the USA (5). This difference may be due to different etiology of ESRD and 
demographic differences between the USA and Europe. In the USA diabetic nephropathy 
is the cause of ESRD in 40 % of the patients, while only 20 % of the patients in Norway 
have this diagnosis. In Norway hypertensive nephropathy was the most commonly 
8reported primary renal diagnosis in incident ESRD patients, constituting  32% of all new 
patients in 2005 (6). 
1.2 Kidney transplantation.  
Although sporadic attempts at kidney transplantation had been made throughout the first 
half of 20th century, the current era of transplantation was pioneered in Boston in 1954 
with live donor transplantation between identical twins (7). In January 1959 the first 
successful kidney transplantation between non-identical twins was performed (8). The 
first attempts at immunosuppression used total body irradiation; azathioprine (AZA) was 
introduced in the early 1960s, and was soon routinely accompanied by prednisolone (9). 
The polyclonal antibody preparations antithymocyte globulin (ATG) and antilymphocyte 
globuline (ALG) became available in the mid 1970s (10). With azathioprine and 
prednisolone as the baseline regimen and ATG or ALG used for induction or for the 
treatment of steroid resistant rejection, the success rate of kidney transplantation was 
approximately 50% at 1 year and the mortality rate was 10% to 29%. The situation was 
transformed in the early 1980s with the introduction of cyclosporine (11). Because the 
results of kidney transplantations were poor, the dramatic benefit of cyclosporine was 
clearly evident. Short-term graft survival rates increased to more than 80% at 1 year. 
Since the mid 1980s cyclosporine based immunosuppression has been the most common 
regimen in use fig 1. 
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Fig. 1a Graft survival uncensored for death in living donor kidney 
transplantation according to identical or one haplo type mismatch before 
and after the introduction of cylosporine in Norway.
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Fig 1b. Graft survival uncensored for death in deceased donor 
transplantation before and after the introduction of cyclosporine in 
Norway.
Torbjørn Leivestad 2007
Although the benefits of cyclosporine were obvious, its capacity to produce both acute 
and chronic nephrotoxicity was soon recognized to be a major disadvantage (12). In 
1985, OKT3, the first monoclonal antibody used in clinical medicine, was introduced 
based on its capacity to treat first acute rejection episodes, although the toxicity of the 
drug tended to restrict its use to episodes of rejection that were resistant to high dose 
steroids (13, 14). In some centers it was used as an induction agent (15). With these 
medications- cyclosporine, azathioprine, corticosteroids and the antibody preparations- 
the transplant community entered the 1990s, achieving success rates of up to 90% in 
many centers and minimal mortality. Tacrolimus was introduced as an alternative to 
cyclosporine (16). Mycophenolate mofetil was found to be more effective than 
azathioprine by virtue of its capacity to reduce the incidence of acute rejection episodes 
(17). In 1999 sirolimus was added to the immunosuppressive menu, and studies are in 
progress to evaluate several new chemical and biologic agents (18). 
Also contributing to the improved graft and patient survival was diagnosis and treatment 
of infections such as CMV as well as the increased focus on cardiovascular disease in the 
transplant population with improved blood pressure control and treatment of 
hyperlipidemia (19, 20). 
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1.3 Kidney transplantation in Norway. 
The first five kidney transplantations in the Nordic countries were performed at 
Rikshospitalet in Oslo by Leif Efskind and his team. The first Norwegian patient was 
transplanted in 1956 (21). However, the patient   died one month after the transplantation 
of a heart attack during another surgery. The next 4 patients died of acute rejection 
episodes of the graft or septicemia between 14 and 40 days post-transplantation. In 1963 
the first successful kidney transplantation in Norway was performed at Ullevål Hospital. 
The operation was performed in collaboration between Ole Jakob Malm and a surgeon 
from Boston, R.E. Wilson, who brought with him AZA (21). From 1983 all solid organ 
transplantations in Norway have been performed at Rikshospitalet. Since 1984, also 
unrelated donors have been used. Acceptance criteria for kidney transplantation have 
been wide and strict age limits have never been applied. This is illustrated in Fig 2 where 
the age of first transplant recipients since 1969 is shown.. 
Fig. 2 Recipient age at first time renal transplantation
1969-82 and annually 1983-2006 in Norway.
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Furthermore, there has been a tradition to encourage living donor transplantation that has 
resulted in a stable rate of living donor transplantation for over 30 years (22). This is 
different from other countries where there has been an increase in the rate of living donor 
transplantation during the last 10 years (23). Donor demographics are also different even 
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in the Nordic countries as shown in fig 3.
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Demographic data on all patients that receive a renal transplant in Norway are transferred 
to the Norwegian Renal Registry. 
1.4 Gender aspects in ESRD 
Male gender is associated with a more rapid progression of renal injury in non-diabetic 
kidney disease (24). In Norway 64.5% of the patients receiving renal replacement therapy 
in 2005 were men (6). Potential mechanisms for gender-related protection in women 
include differences in renal structure including glomerular number and size, renal 
hemodynamics, and different effects of estrogen or androgen on the synthesis and release 
of vasoactive substances, growth factors and cytokines. In a study of potential kidney 
donors where glomerular filtration rate (GFR) was measured, the age dependent decline 
in kidney function between 20 and 50 years of age was more pronounced in men than in 
women (25). It was speculated that pre-menopausal females was protected by estrogens, 
however, this was not specifically investigated.  
The role of sex hormones in modulating the activity of several regulatory systems, 
including the rennin-angiotensin system (RAS), has been suggested as an explanation for 
the slower progression of non-diabetic renal disease in women. Clinical support for this 
hypothesis is provided by the REIN study, which reported that women with proteinuric 
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renal diseases exhibited greater reductions in proteinuria and better renal outcomes in 
response to ACEIs than did men, despite similar blood pressure control (26). 
Furthermore, the etiology of ESRD may differ in men and women. There are reports of 
more men with chronic glomerulonephritis while there is a predominance of women with 
tubulo-interstitial disease (27, 28). The importance of these differences is not explored in 
the literature. 
1.5 Acute rejection episodes. 
Acute renal allograft rejection is defined as an immunologic process resulting in a 
detoriation in allograft function that is associated with specific pathologic changes. These 
changes have been standardized by the Banff criteria (29). The allograft biopsy remains 
the gold standard for confirming the diagnosis of acute rejection.  
In the 1980s, at least one acute rejection episode occurred in 50 to 60% of renal allograft 
recipients (30). In Norway acute rejection episodes occurred in 48 - 82% according to 
HLA-DR mismatch during the early 1990s (31). With newer immunosuppressive 
regimens many centers are achieving acute rejection rates below 15%, and only 13% of 
kidney transplant recipients in 2003 required therapy for acute rejection in the USA (32) 
It has been reported that early acute rejection episodes (occurring within 60 days of 
engraftment) have a major effect on allograft survival (33). According to these reports 
kidneys that recover function still have a 10% decrease in one-year survival when 
compared to rejection free kidneys (30). This is the reason why early acute rejection 
episodes have been used as surrogate endpoint for future graft loss in many studies. 
However, despite decreasing rates of acute rejection episodes, and improved 1 yr graft 
survival, an overall lack of improvement in long-term allograft survival is reported in 
recent publications (34, 35). Although the underlying reasons are unclear, this may be 
related to a higher proportion of acute rejection episodes that fail to recover to previous 
baseline function (35). In addition the use of potent induction agents may prevent acute 
rejection in predisposed recipients. Still, these patients may develop subclinical rejections 
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resulting in significant tubulo-interstitial damage to the transplanted kidney with reduced 
graft survival as the result (36, 37). It follows that, an acute rejection episode is not a 
satisfactory surrogate end-point for graft survival today. 
1.6 Graft survival 
Graft survival is one of the most important measures of success in kidney transplantation. 
However, since one-year graft survival rates generally increased to 90% in 1996, it has 
been difficult to use short term graft survival as a sensitive measure of progress in 
transplantation (35, 38). As the recipient population has aged by nearly 10 years over the 
past decade, the prospects for long term survival are hampered by age related problems. 
The recipient age obviously has a very clear effect on causes of graft loss. Fewer than 
20% of grafts in patients over the age 60 yr are lost because of acute or chronic rejection 
while 50 % of the graft losses are due to patient death (39, 40). Donor age is also an 
important risk factor for reduced graft survival. In response to organ donor shortage, 
there has been a broadening of the age limits traditionally applied to organ donors. This 
has resulted in an increase in donor age over the years in both deceased and living donor 
transplantation (6) 
In general, living donor grafts are superior to deceased donor grafts (2, 32). This benefit 
applies across all degrees of HLA mismatching (41). The better outcomes reflect several 
factors: healthy living donors, avoidance of ischemia-reperfusion injury, high nephron 
mass and probably the effect of shorter waiting time for the recipient. Excellent results 
are now being demonstrated with living unrelated kidney transplantation where HLA 
matching is not optimum (42).  
1.7 Cardiovascular disease and mortality after transplantation. 
Renal transplant recipients may develop a variety of complications related to the 
allograft, the immunosuppressive therapy, progression of pre-existing diseases, and aging 
with the appearance of new diseases. Allograft failure is usually defined either by death 
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or by a patient’s need to undertake new treatment for ESRD (i.e., chronic dialysis or 
retransplantation). To improve graft survival approaches to prevent death and graft failure 
must be undertaken. 
Death with graft function accounts for 40% to 50% of all graft losses (43). The three 
most commonly defined causes of death in the late post transplant period are 
cardiovascular disease, infection and malignancy (44).Studies of renal transplant 
recipients in the late 1980s  and early 1990s showed that ischemic heart disease  alone 
caused as much as 53% of the deaths with a functioning graft in Scandinavian transplant 
recipients(45). However, the relative risk of CHD has progressively decreased since the 
1990s along with a 50% reduction in post-myocardial infarction mortality. This 
improvement has occurred despite the increase in renal transplant surgery in older 
patients. 
To understand how to prevent post transplant CVD deaths and complications, it is crucial 
to define the etiological risk factors. Identifying risk factors is important for two reasons. 
Some risk factors can be modified, and for some of these, there is strong evidence from 
studies that intervention improves survival (20). It is also important, however, to identify 
risk factors that cannot be modified because these risk factors help to identify high-risk 
patients who can be targeted for screening, as well as for treatment of modifiable risk 
factors after transplantation. Transplantation confers additional risks for CHD because 
key immunosuppressive medications can cause hypertension, hyperlipidemia, impaired 
glucose tolerance and allograft dysfunction. Consequently, coronary risk factors specific 
for transplantation, such as the use of steroids, calcineurin inhibitors and post-transplant 
diabetes mellitus, may be in transition to becoming modifiable risk factors. 
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2. AIMS OF THE STUDIES  
The aims of this thesis were to evaluate gender related issues in renal transplantation. 
More specifically the primary purposes were to assess:  
- Whether there is a predominance of female-to-male donations among first time living 
donor kidney transplantation in Norway. 
- The effect of donor gender and age on outcomes after a first time living donor renal 
transplantation.  
- Gender differences in cardiovascular events and total mortality in recipients of a kidney      
transplant. 
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3. SUBJECTS AND METHODS 
3.1 Study population 
The Norwegian Renal Registry 
National data on renal replacement therapy has been collected within the Renal 
Association since 1980. In 1994 the Norwegian Renal Registry was formally constituted 
as collaboration between The Norwegian Renal Association and Rikshospitalet 
University Hospital, with the latter as the formal owner. The Registry has obtained 
concession from the National Data Inspectorate. The study protocols of paper I and II 
have been approved by  National and Regional Committees for Research Ethics in 
Norway. 
The data base contains donor variables: age, gender and relationship to the recipient, 
recipient variables: age, gender, original disease, time spent on dialysis, time spent on the 
waiting list, panel reactive antibodies, transplant factors: human leukocyte antigen [HLA] 
–A, -B, and –DR mismatches, and post transplantation features including 
immunosuppressive regimen, rejection history, patient survival, graft  survival and serum 
creatinine values. Serum creatinine values, causes of death or graft failure have been 
reported yearly throughout the whole study period.  
In paper I all first time LD transplantations performed between 1984 and 2002 are 
included in the study. In paper II data on first time LD transplantation performed between 
January 1,1994 and December 31, 2004 in recipients and donors above 18 years of age 
were analyzed. Only one patient was lost to follow up in this cohort due to emigration. 
This patient was not included in the analysis.  
ALERT study 
The Assesment of LEscol in Renal Transplantation (ALERT) study recruited 2102 renal 
transplant recipients from nephrology and transplant clinics in Belgium, Denmark, 
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Finland Germany, Norway, Sweden, Switzerland, the UK and Canada. This is the first 
large-scale clinical trial to address the cardiovascular complications of renal 
transplantation. Men and women aged 30-75 years who had received renal or combined 
renal pancreas transplants more than 6 months before randomization and who had stable 
graft function were recruited. Patients were included from June 1996 until the end of 
October 1997. The median time since transplantation was 4.5 yr, and the median follow-
up time was 5.4 yr. All patients were receiving immunosuppressive therapy with 
cyclosporine and had total cholesterol concentrations of 4.0-9.0 mmol/L. Patients with a 
history of myocardial infarction more than 6 months before randomization could be 
enrolled if their total cholesterol concentration was 4.0-7.0 mmol/L. Patients were 
excluded if they were on statin therapy, had familial hypercholestrolaemia or had 
experienced an acute rejection episode in the 3 months before randomization. In addition, 
patients with a predicted life expectancy of less than 1 yr were excluded. Only patients in 
the placebo arm of the study (n=1052 patients) was evaluated in paper III. This was 
considered to be the best way to evaluate the impact of different cardiac risk factors over 
time in a statin naïve population. The predefined end points used in this study were 
cardiac death or definite non-fatal myocardial infarction verified by hospital records and 
total mortality. Electrocardiographic changes were classified according to the Minnesota 
code. The study adhered to the International Conference on Harmonization guidelines for 
Good Clinical Practice and was in accordance with the Declaration of Helsinki. All 
participants provided written informed consent, and the ethics committees in each 
participating country approved the trial (20). 
3.2 Statistical analyses 
Continuous data are expressed as mean ± 1 standard deviation (SD) and proportions were 
expressed as percent. Quartiles are given when the distribution is skewed. 
Independent Samples T-test and Chi-square statistics- were used to examine for baseline 
differences between two means or proportions in all papers. All tests are 2-sided, and a 
significance level of 5% was used. All analyses were performed with SPSS 12.0. 
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Survival analyses 
Survival analysis is concerned with studying the time between entry to a study and a 
subsequent event. Censored survival times occur if the event of interest does not occur 
for a patient during the study period. When examining graft survival after kidney 
transplantation, graft survival censored for death and graft survival uncensored for death 
are most frequently used. When graft survival is censored for death only graft failures are 
considered.  When graft survival uncensored for death is evaluated graft losses and 
patient death with a functioning graft are evaluated. In the relatively old kidney transplant 
population in Norway, recipient age gives a large contribution to the result when graft 
survival uncensored for death is utilized.  
Kaplan Meier analyses 
The Kaplan Meier is a univariate analysis that produces a plot of the survival curve for 
each group of interest. There are, however, two important methodological limitations. 
First, only the influence of categoric variables can be estimated because the analysis 
cannot deal with continuous variables. Secondly, the importance of a specific variable 
cannot be tested if adjustment for the whole set of other relevant variables is required. 
Moreover, this non-parametric analysis can only test global differences in survival curves 
between groups. On the other hand, the main advantage with Kaplan Meier plots is that 
the readers are used to this way of presenting the data and it shows clearly the time to the 
event. 
Cox analysis 
The Cox proportional hazard model is a robust mathematical model where a number of 
independent continuous and categorical variables on survival can be studied 
simultaneously. One of the assumptions of the Cox model is that for any two patients, the 
ratio of their hazards across time is a constant. This assumption has been tested in the 
three papers in a log-minus-log survival plot. The number of variables that can be 
included in the study is limited, but does not depend on the number of patients but on the 
number of events occurring in these patients. As a rule, the maximum number of 
variables that can be included in the analysis equals 10% or the square root of the number 
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of events. Although the number of variables is limited it is important to include those 
variables that are supposed to influence the outcome. It is important to be aware of that 
multivariable analysis can never adjust for unknown or unmeasured confounders. There 
are several methods for variable selection depending on which type of model that is 
constructed. 
In an explanatory model, the goal is to correctly characterize the relationship of each 
predictor to the outcome variable. For that purpose, the identities of the variables in the 
model are critical, and one has to take great care in choosing which variables to include 
and in what mathematical form. Using statistical significance levels in the univariate 
analysis to choose potential confounders to include in this kind of model is not a very 
good idea. That is because the amount of confounding depends on two associations, the 
relation between the potential confounder and the exposure and the relation between the 
potential confounder and the outcome. The coefficient that is tested for significance in a 
stepwise algorithm evaluates only the relation between the potential confounder and the 
outcome, but it ignores the relation between the potential confounder and exposure. This 
method can thus only include variables that are not confounding. It can also omit 
variables that are confounding, but for which the relation with the outcome is not 
statistically significant. This kind of multivariate Cox model was constructed in paper II. 
Predictive models try to predict outcomes for patients with particular characteristics. This 
kind of model was constructed in paper III where p values in the univariate analysis was a 
selection criterion. Even if a prediction model is reliable, it may not be useful in clinical 
practice for several reasons. It may require clinicans to have certain laboratory results that 
may not be available, or it may have been developed and validated on patients different 
from those seen in clinical practice. 
Interaction 
An interaction occurs when the impact of a risk factor on outcome is changed by the 
value of a third variable. Interaction is sometimes referred to as effect modification, since 
the effect of the risk factor on outcome is modified by another variable. In extreme cases, 
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an interaction may completely reverse the relationship between the risk factor and the 
outcome. This would occur when the risk factor increased the likelihood of outcome at 
one value of the interaction variable but decreased the likelihood of outcome at a 
different value of the interaction variable. Paper II a sex difference in susceptibility to age 
as a risk factor in donor kidneys on graft loss was explored by testing for biological 
interaction according to Rothman (46). 
Gender 
Several questions regarding the impact of donor and recipient gender on CHD, patient 
and graft survival after kidney transplantation arise. In paper III male and female 
transplant recipients have been evaluated separately. The reason for this is that women 
and men differ biologically, and these differences can, in general, affect risk factors and 
outcomes. When gender only is included in a multivariate model, the sex related 
differences in degree of exposure of different risk factors are lost.  
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4 RESULTS 
4.1 Paper I 
Gender imbalance among donors in living kidney transplantation: the Norwegian 
experience. 
Gender demographics and outcomes of first time living donor transplantations in Norway 
performed in the period 1985-2002 were assessed in this paper. 
Of 1319 first time kidney transplantations performed in the study period, females 
constituted the majority of the donors (57.8%; p<0.001) and men the majority of the 
recipients (62.7%; p<0.001). The donors were related in 88.3% of the population. Of the 
220 unrelated donors, 90.5 % were spouses and 9.5 % friends or family members by law. 
Siblings constituted the largest group of LRD, and there was no significant difference 
between the frequency of donation between brothers and sisters. The second largest 
group of donors was parents donating to their children. Mothers were more often donors 
than fathers (p<0.001). This gender difference was, however, only apparent when the 
recipients were 30 years old. The proportion of child-to-parent donation was 10.6% of 
all LD transplantations, and there was no gender difference among the donors (p=0.69). 
Of the spousal donors the majority was females (65.8%). 
Females received a kidney from male and female donors with the same frequency (248 
vs. 244; p=0.86). In opposite sex pairs the female to male donations were as expected 
based on the incidence of ESRD and gender make up in the general population. However, 
the female to female donation rate was higher than expected and the male to male 
donation rate lower than expected. 
 There was no difference in the number of early acute rejections according to donor sex. 
Donor sex did not affect graft survival uncensored for death (p=0.75). Donor age had a 
substantial impact on serum creatinine values after transplantation. 
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4.2 Paper II 
Living donor kidney transplantation: The effects of donor age and gender on short- 
and long-term outcomes. 
The aim of this paper was to assess the influence of donor age and gender on short-term, 
graft survival, < 5 years after transplantation,  long-term graft survival beyond 5 yr after 
transplantation and acute rejection episodes in first time LD transplantation. 
In this study 739 first time LD transplantations in recipients above 18 years performed 
between January 1, 1994 and December 31, 2004 were evaluated. The recipients were 
followed until graft loss, death or last recorded status up to June 30, 2005. Only early 
acute rejection episodes occurring within 3 months after transplantation were included in 
the analysis. There were 71 graft losses during the study period and 74 patients died with 
functioning grafts. In the donor population 346 (46.8%) were above 50 years and donor 
age remained fairly constant throughout the study. 
In the Cox multivariate model of risk factors for acute rejection episodes recipient age 
50 years decreased the risk of experiencing an acute rejection episode (HR 0.69; 95% 
CI 0.55-0.87). Donor age 65 years (HR 1.57; 95% CI 1.09-2.27) and number of HLA 
DR mismatches were predictors for acute rejection episodes.  
In the multivariate analysis of risk factors for death censored graft survival donor age 65 
years was a risk factor in all time periods after transplantation. During the first 5 years 
after transplantation, short term follow-up, a steroid resistant rejection episode was an 
additional risk factor (HR 3.96; 95% CI 1.46-10.75). 
Long term follow-up, more than 5 years after transplantation, male donor gender was the 
only additional risk factor for graft loss (HR 3.58; 95% CI 1.57-8.17). A sex difference in 
susceptibility to age as a risk factor in donor kidneys on graft loss was explored by testing 
for biological interaction.  No interaction between donor sex and age was found. 
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4.3 Paper III 
Gender-associated risk factors for cardiac end points and total mortality after renal 
transplantation: post hoc analysis of the ALERT study. 
The aim of the present article was to explore whether renal transplantation restores the 
gender-dependent cardiac protection in women. The distribution of risk factors and their 
impact on cardiac outcome and total mortality in men and women were also evaluated.  
This post hoc analysis of pre-defined end points in the placebo group (n=1052) of the 
ALERT study provided an opportunity to evaluate the impact of the different risk factors 
over time in statin-naïve renal transplant recipients. The mean age was 50.1±11.1 years 
and 65.3% of the study population was males. At baseline HDL cholesterol levels were 
higher in women than men (1.48±0.002, p<0.0001). No differences in LDL cholesterol 
levels or triglyceride levels were observed. Furthermore, more men than females had ST-
T abnormalities in ECG at baseline (147 (21.4%9 vs. 52 (14.2%), p=0.0046). There was 
also more men than women who had left ventricular hypertrophy at baseline (121 
(17.6%) vs. 35 (9.6%), p=0.0005).  
 A total of 104 patients experienced a definite non-fatal MI or cardiac death, and 138 
patients died of any cause. There was no gender difference in the occurrence of any of 
these end points. 
 In the multivariate analysis for the cardiac end-point, previous coronary heart diseases 
(HR 3.21; 95% CI 1.55-6.45), diabetes (HR 1.96; 95% CI 1.01-3.83), treatment for 
rejection (HR 2.32; 95% CI 1.22-4.42) and serum triglycerides (HR 1.29; 95% CI 1.07-
1.56) were predictors in men. In women the LDL/HDL ratio (HR 1.70; 95% CI 1.30-
2.23) was the only significant risk factor. 
 A slightly different risk factor pattern appeared in the Cox multivariate analysis for total 
mortality. Diabetes (HR 1.96; 95% CI 1.01-5.50), ECG abnormalities (HR 1.15; 95% CI 
1.10-1.20), plasma triglycerides (HR 1.28; 95% CI 1.05-1.57), serum creatinine (HR 
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1.09; 95% CI 1.05-1.13) and age at baseline (HR 1.09; 95% CI 1.05-1.13) predicted total 
mortality in men, while ECG abnormalities (HR 3.41; 95% CI 1.42-8.24), age at baseline 
(HR 1.07; 95% CI 1.01-1.13) and LDL/HDL ratio (HR 1.32; 95% CI 1.01-1.74) were 
predictors in women. 
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5. DISCUSSION 
5.1 Methodological considerations. 
When renal transplantation was a new treatment method for ESRD, graft failures, patient 
deaths and cardiac events were more prevalent and successes could be directly derived 
from facts and events. Results have improved dramatically over the last decades and 
many factors have seemed to be involved in these continuously improving results. The 
multitude of risk factors present makes it difficult to ascertain the individual contribution 
of each factor. Therefore multivariable analysis is needed because most outcomes have 
multiple causes, and both prognosis and the etiology are usually influenced by a large 
number of factors. Identification of risk factors through observational studies has been 
particular important because it is not possible to randomize people to many of the 
conditions that cause inferior outcomes after a transplantation. Causality, however, is 
established on the basis of biological plausibility and rigorous study designs. Although 
the result of an epidemiological study may reflect the effect of an exposure on the 
development of disease, it is also possible that the findings may have an alternative 
explanation. Our results should therefore be evaluated in this context. An overall goal of 
an epidemiological study is accuracy in estimation. To achieve this, the study should be 
designed and conduted with the aim of reducing random and systematic errors (46). 
Precision (lack of random error) 
The primary way to increase precision in an epidemiological study is by increasing the 
size of the study. Random error is the variability in the data that we cannot readily 
explain. The degree to which chance may account for the results can be evaluated by tests 
of statistical significance. The P-value is defined as the probability that an effect could 
have occurred by chance alone. It is a statistic that can be viewed as a measure of the 
compatibility between the data and the null hypothesis A more informative measure of 
the role of chance is the confidence interval (CI), which is an expression of the amount of 
random error in the estimate. A wide CI indicates low precision and increase the 
probability that some of the results may be due to chance. 
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Validity (lack of systematic error) 
The validity is usually divided into two parts: Internal and external. Internal validity is 
defined as the degree to which the results of an observation are representative for the 
particular group of people being studies. External validity or generalization is the extent 
to which the results of a study apply to people outside the population being studied. 
Internal validity 
A study can be biased because of the way in which the  subjects have been selected, the 
way the study variables are measured, or some confounding factor that is not completely 
controlled.  These errors remain even in an infinitely large study and are also called 
systematic errors.  
a. Selection bias 
Selection bias in a study stems from the procedures used to select subjects and from 
factors that influence the study participation. Although one might expect minimal 
sampling error when using the Norwegian Renal Registry because it is a national based 
registry following the patients for the rest of their lives, it should be standard to treat all 
epidemiological studies as having sampling errors. When looking at the ALERT trial it 
should be recognized that the overall statistical power of the study was low. The size of 
the ALERT study was based on registry data from the Scandinavian countries, which 
estimated a primary endpoint rate of 5% per year. The cardiovascular risk and 
cardiovascular event rate among the recruited study population was low. In a post hoc 
analysis, based on a 17% reduction in the chosen primary endpoint, it was estimated that 
6800 renal transplant recipients followed for 5 years would be required to provide 80% 
power and Į=0.05 two-tailed. This study is, however, the biggest randomized trial 
performed in renal transplant recipients. 
b. Information bias 
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 Information or observation bias includes any systematic error in the measurement on 
exposure or outcome. Misclassification of subjects for either exposure or disease can be 
differential or non differential. These terms refer to the mechanism for misclassification.  
Misclassification of exposure is non differential if it is unrelated to the occurrence or 
presence of disease and differential if the misclassification of exposure is different for 
those with and without disease. Similarly, misclassification of disease is non differential 
if it is unrelated to exposure, otherwise it is differential. Non differential misclassification 
between two exposure categories will in general make the effect estimates for those two 
categories converge toward one another.  
The high numbers of cardiovascular events in renal transplant recipients reported to 
registries are  differential misclassifications. It has been much easier to report a 
cardiovascular event in a kidney transplant recipient because it is a well known fact that 
cardiovascular disease and mortality is much higher in this group than in the general 
population. This problem is avoided in randomized clinical trials where a committee 
adjudicates the events. An independent critical events committee of two nephrologists 
and two cardiologists reviewed all end points for adjudication in the ALERT trial. 
Therefore, the patients who get the diagnosis of a MI are correctly diagnosed in paper 3. 
The parameters in paper I and II are not likely to be affected by differential 
misclassification. 
c. Confounding 
Confounding occurs when the apparent association between a risk factor and an outcome 
is affected by the relationship of a third variable to the risk factor and to the outcome. For 
a variable to be a confounder, the variable must be associated with the risk factor and 
causally related to the outcome. 
The effect of confounders may be adjusted for by multivariable analysis or stratification. 
Stratification works well when there are only two or three confounders. However, when 
there are many potential confounders, stratifying for all of them will create literally 
hundreds of groups. In this thesis we have used proportional hazard (Cox) regression. A 
major advantage of proportional hazard analysis is that it includes persons with varying 
lengths of follow-up. Unmeasured factors that could explain the result should always be 
28
considered. In our papers we have no information on life style related factors as alcohol 
consumption, physical activity and dietary nutrition intakes in either the registry data or 
the ALERT placebo group. 
External validity 
For a result from a randomized controlled study or epidemiological study to be clinically 
useful, it must be relevant to a definable group of patients. Lack of external validity is the 
most frequent criticism by clinicians of studies, systematic reviews and guidelines, and is 
one explanation for the widespread under use in routine practice of many treatments that 
have been shown to be beneficial in trials and that are recommended in guidelines. 
Another problem for the external validity of a study is an inadequate duration of 
treatment and/or follow-up. Furthermore, the external validity of a trial also depends on 
whether the outcomes are clinically relevant. There are many examples of treatments that 
have had a major beneficial effect on a surrogate outcome, which had previously been 
shown to be correlated with a relevant clinical outcome in observational studies, but 
where the treatments have proved ineffective or harmful in subsequent large randomized 
controlled trials that used these same clinical outcomes (47, 48).  
Regarding the gender demographics of Norwegian living donors given in paper I the 
external validity is high as there are no missing data on this issue in the registry. The 
outcomes after transplantation, early acute rejection episodes, graft loss censored for 
death and uncensored for death that are reported in paper I and II are not surrogate 
endpoints and all have been reported to the registry. In paper III, however, the results 
may be applicable only to long time survivors after a renal transplantation with a good 
graft function. 
5.2 Importance of results 
Donor epidemiology (paper I) 
Our main result in this article is that although the majority of living kidney donors in 
Norway is women, there has been no predominance of female to male donations in 
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Norway during the last two decades. It has been reported from other centers that women 
donate to men and children to a greater degree than men do (49, 50). This has been 
explained by women having greater obligations to their families as well as economical 
reasons. Albeit the majority of the donors are women, and no difference in female to 
male donations was found, the overall higher number of female donors was caused by a 
higher female to female donation rate than expected. In a recent Scandinavian study it 
was found that there were only minor differences in attitudes regarding kidney donation 
between men and women (51). Thus the rather small gender difference could be due to 
LD kidney donation having been strongly advocated as a treatment option for ESRD in 
Norway for over 30 years.  
 A rather surprising finding was that fathers were as likely as mothers to donate to 
younger children. This is in contradiction to reports from the USA where mothers were 
especially prone to donate to younger children and this was explained by the strong 
emotional bondage between mother and child (49). The result is especially stunning as 
the system for reimbursement of lost income is not optimal in Norway. Westlie et al. 
have reported that 21% of Norwegian donors experienced an economic loss (22). One 
might be tempted to speculate that the care of small children is equally shared among 
mothers and fathers and this may override the disadvantage of poor reimbursement. 
Our finding that the frequency of wife to husband transplantations mirrors the incidence 
of ESRD in men in Norway differs from reports from other countries. In a report from 
Canada 90% of the spousal transplantations were from wife to husband (52). 
Furthermore, in opposite sex pairs in living related transplantation  the observed donation 
rate was similar to what could be expected based on the gender composition in the 
general population and in the incidence of ESRD.  
Short and long term outcomes after living donor kidney transplantation (paper II) 
Our main result in paper II was that a donor age 65 year was a risk factor for graft loss 
in recipients with more than 3 months graft survival. In deceased donor transplantation 
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donor age 50 years has been associated with reduced graft survival in the recipient (53). 
In Norway there has never been a strict age limit for donors or recipients. In the study 
period 46.8% of our donors were above 50 years. It is therefore a study population where 
evaluation of outcomes after kidney transplantations with donors above 50 years can be 
done. Fig 4 shows death censored graft survival in recipients of living donors in 3 age 
categories. 
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Fig 4. Death censored graft survival
according to donor age in paper II.
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P<0.00001
RR<50 yr=1.00
RR 50-64.9 yr =1.74 (1.03-2.92)
RR 65 yr=4.60 (2.39-8.85)
No at risk:
  Our result is supported by the findings in a paper by Gill et al where the risk of graft 
loss with living donors 55-64 years was similar to that with deceased donors <55 years. 
Their conclusion was that outcomes are excellent with living donors <65 years (54). The 
implication of our results is that although graft survival with LD>65 yr is inferior to 
younger donors; this source of donors should still be exploited. As shown in our study, 
older donors can be successfully used for older recipients. Already an old for old program 
exists in DD transplantation. Perhaps this strategy should be utilized further in living 
donor transplantation programs.  
We found that a donor age 65 years is a risk factor for an early acute rejection episode 
in LD transplantation, while it has been observed that donor age above 50 yr is a risk 
factor for an early acute rejection episode in recipients of kidneys from deceased donors 
(53). Our result in living donor transplantation represents a 15-year shift in donor age 
compared with deceased donor transplantation regarding the risk of early acute rejection 
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episodes. How much impact an early acute rejection episode has on later graft loss today 
is not established. Our finding that only a steroid resistant rejection episode was a risk 
factor for early graft loss is in accordance with other recent reports. Meier Kriesche et al 
showed that early rejection episodes where creatinine was normalized back to baseline 
levels was no predictor for later graft failure (35). In our study a steroid resistant rejection 
episode was no longer a risk factor for graft loss 5 years after transplantation. This may 
not be a surprise as other factors may be stronger predictors by then (55). These findings 
are in disagreement with the use of acute rejection episodes as a surrogate endpoint. 
Donor age, however, should be used as one factor in the total risk score for graft loss as 
well as when adjustment of immunosuppressive medication is considered. 
A rather surprising finding in our study was that male donor gender was a risk factor for 
graft loss for the whole period as well as for long term graft survival beyond 5 years. 
There are few publications on long term results in LD transplantation and especially with 
a gender perspective. Earlier studies have reported poorer overall graft survival in 
females donating to males, and this was explained by the theory of nephron underdosing 
(56, 57). In an autopsy study, however, there was no gender difference in the number of 
glomeruli (58). Individuals with larger kidneys had more glomeruli and older individuals 
had fewer glomeruli. Furthermore, the increased kidney weight seen in men was solely 
dependent on greater body surface area (58). These results have been supported in a study 
where kidneys from living donors were weighed after the donor nephrectomi. The mass 
of kidneys from men and women were not statistically different. Furthermore, no 
difference in graft survival until 3 years after transplantation by donor and recipient 
gender were found in this study (59). Before the introduction of cyclosporine, no 
difference in graft survival between male and female donor kidneys was reported (60). 
 To evaluate whether our result was due to a biological interaction between donor age and 
sex, an interaction analysis was performed Table 1. 
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Table 1. 
 Incidence of graft loss and excess RRs because of biological interaction (RERI) between 
donor age and sex.  
DONOR GRAFT LOSS 
Whole period 
(n=739) 
RR (95% CI) RERI (95% CI) 
Female <50 yr 0.86/100 pt yr 1.00  
Male<50 yr 1.75/100 pt yr 2.03 (0.91-4.60)  
Female>50 yr 2.35/100 pt yr 2.73 (1.29-5.92)  
Male >50 yr 3.46/100 pt yr 4.02 (1.86-8.96)  
  0.26 (-2.10-2.62) 
            
 NOTE. RERI=0 means no interaction. RERI=0.5 means that because of interaction 
between the 2 risk factors, the RR is 0.5 greater than expected based on the addition of 
the 2 risk factors. 
 No interaction between donor gender and age was found in our study..  
The implication of our study is that donor age, as a risk factor for acute rejections, should 
be considered in the choice of immunosuppressive regimen. Furthermore, donor gender 
should not be an important issue in donor selection. 
Cardiovascular events and total mortality after renal transplantation (paper III) 
The main result in this paper is that no difference in either the incidence or time to 
cardiac events and total mortality was observed in male and female transplant recipients.  
It is well known that women develop angina and MI later than men. This difference is 
confirmed in a Finnish report in the general population where the difference in CHD 
incidence and mortality in men and women was largest in persons below 50 years (61). 
Data from Norway is lacking, however there is a similar difference in cardiovascular  
mortality (Fig 5). 
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This is, however, not the case in dialysis patients where the female gender advantage is 
lost (62). In a Norwegian cross sectional study of renal transplant recipients multivariate 
analysis revealed that ischemic heart disease was independently related to male gender 
(63). This is in contrast to our result, the reason for this discrepancy is not known. In the 
follow-up study by the same authors, however, in which data was collected 5 yr after 
baseline, no difference between men and women regarding ischemic heart disease was 
found in the multivariate analysis (64). The fact that no difference in cardiac events and 
total mortality was observed in our study of a   relatively low risk population of transplant 
recipients, suggests that the female gender advantage regarding CHD is not restored 
following a successful transplantation. When the study population was recruited between 
June 96 and October 97, patients who were considered to have a high CHD risk were 
already receiving lipid lowering therapy and were not eligible for the study. However, a 
relatively low risk transplant population is at a much higher CHD risk than the age 
matched general population. When compared to the general population, cardiovascular 
mortality in transplant recipients is increased by nearly 10-fold among patients with the 
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age range of 36 to 44 and at least doubled among those between the ages of 55 to 64 
(65,62).
At baseline more men than women had ST-T abnormalities in the ECG. This is in 
contrast to findings in community based cohorts where women have significantly more 
ST changes and T wave abnormalities (66). This may indicate that only the healthiest 
women were randomized in our study. The prevalence of LVH at baseline was lower than 
reported by Midtvedt et al 1 year after transplantation where 45% of the recipients still 
had LVH. At baseline in their study 66% of the patients had LVH. Our results may imply 
that good blood pressure control after transplantation leads to regression of LVH in both 
men and women beyond 1 year after transplantation (67). 
Baseline demographic data show that LDL cholesterol levels were the same in men and 
women who were 50 yr old.  Women usually have lower levels at that age. In both sexes, 
the risk of CHD increases markedly with age. In most populations, serum cholesterol 
increases with age. In men, this increase usually levels off around the age of 45 to 50 
years, whereas in women the increase continues sharply until the age of 60 to 65 years 
(68). The lack of difference in these subjects could be caused by immunosuppression, 
diabetes, reduced kidney function and history of CKD. One limitation is that we do not 
have any data on hormonal status in the women who participated. In the general 
population an early menopause is associated with increased ischemic heart disease 
mortality (69). 
Regarding the impact of different lipid parameters on the cardiac end-point, a gender 
difference appeared in the multivariate analysis. In women the LDL/HDL cholesterol 
ratio was the only lipid parameter that remained a risk factor for the cardiac end-point. 
Our result   is in accordance with a report from the Nurse’s Health Study where lipid 
indexes, such as LDL/HDL cholesterol ratio, which reflects the proportion of atherogenic 
to antiatherogenic lipid fractions, was a powerful tool for predicting CVD among 
postmenopausal women (70). Furthermore, it has been shown that among women with 
the highest absolute risk of CAD, those aged >65 years, a low HDL cholesterol level was 
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the only significant lipid predictor of risk for CAD death in a meta analysis. A reduction 
in LDL cholesterol particle size in association with age, menopause and adiposity has 
been found in women. This may explain why high LDL cholesterol levels have been 
shown to affect women less in large epidemiological studies and the benefit of statins for 
the primary prevention of atherosclerotic CVD in women has not been established. 
However, secondary prevention trials support the efficacy of treating women who have 
established vascular disease with statin to lower LDL cholesterol levels. This may be due 
to the reduction in the LDL cholesterol particle size in these women. The average age of 
the women in our study is 50 years, but their risk factor profile is more like that of 
women in the general population above 65 years. 
 The main clinical implication of our study is therefore that women should receive CV 
prophylactic treatment at the same intensity as men. 
5.3 Future research 
Risk factors for cardiovascular incidents and mortality have not been analyzed in the 
Norwegian transplant recipients. These events are available in the registry and are very 
important for the patients and should be examined in the future. Furthermore, the use of 
different medications in men and women should be evaluated. In the placebo arm in the 
ALERT study gender related differences in the use of cardiovascular medication were 
observed. Whether this is the case in the Norwegian transplant population is not known 
nor if any differences in the use of medication have any implications on the outcome in 
the renal transplant recipients.  
Graft survival after living donor transplantation has always been considered to be better 
than after deceased donor transplantation. Whether this still is the case today has not been 
elucidated in patients who have been transplanted more recently..  
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Investigation of how the outcome of an acute rejection episode influences graft survival 
should be explored in the Norwegian transplant population. It has been stated  that in 
transplant recipients where the serum creatinine after  the  treatment for the acute 
rejection episode return to baseline,  graft survival is equal to recipients who have not 
experienced an acute rejection episode.   
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6. CONCLUSIONS AND IMPLICATIONS 
Paper #1 
In opposite-sex pairs the female-to-male donation rate is similar to what could be 
expected based on the gender composition in the incidence in ESRD and gender make-up 
of the general population. 
The implication of this result is that in order to maintain this situation, a continued work 
on attitudes towards donations in both men and women should be continued and the 
system for reimbursement should be improved. 
Paper #2 
In LD transplantation donor age up to 65 years provide excellent long term results. 
Female donor sex may convey superior long term graft survival compared to male donor 
sex.
Our findings support the use of all available donors as long as the medical criteria are 
met. An old for old program in living donor transplantation should be advocated. 
Paper #3 
No gender difference in cardiac events or total mortality was observed in this relatively 
low-risk population of renal transplant recipients suggesting that the female gender 
advantage regarding CHD and survival is not restored following transplantation. 
The implication of this result is that great emphasis should be placed on prophylaxis for 
cardiovascular disease in renal transplant recipients irrespective of gender.  
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